Phase II Trial of Concurrent Cisplatin/Docetaxel and Radiotherapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small Cell Lung Cancer

Patients must have either hist. or cyto. proven newly diagnosed Stage IIIB (N3 or T4) single, primary bronchogenic non-small cell lung cancer (adenocarcinoma, non-lobar and non-diffuse bronchioloalveolar cell carcinoma, large cell carcinoma, or squamous cell carcinoma). Histology or cytology from involved mediastinal or supraclavicular lymph nodes alone will be allowed if a separate distal primary lesion is clearly evident on radiographs (i.e., a second biopsy will not be required); pts. with any brain mets are ineligible (all patients must have a pretreatment CT or MRI of the brain to evaluate for CNS disease); pts. with two or more parenchymal lesions on same or opposite sides of the lung are ineligible; pts. with malignant pleural effusions or with pericardial effusions are ineligible; pts. must have measurable or non-measurable disease (per Section 1.1) documented by CT, MRI, X-ray or physical exam. Measurable disease must be assessed w/in 28 days prior to registration, non-measurable disease assessed w/in 42 days prior to registration; pts. must not have received any prior chemotherapy or radiotherapy for lung cancer; pts. must not have had a previous surgical resection; however, patients may have undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar surgery for the purpose of determining diagnosis, stage, or potential resectability of newly diagnosed lung tumor; pts. preregistration FEV1 must be either >= 2.0 liters, if < 2.0 liters, then the predicted FEV1 of the contralateral lung must be > 800 cc based on the quantitative split function testing (predicted FEV1 = FEV1 x % perfusion to uninvolved lung from quantitative lung V/Q scan report) OR the predicted post-treatment FEV1 is judged by the radiation oncologist to be >= 1 liter.